Shares of Cytosorbents Corp (NASDAQ:CTSO) fell 5.9% during trading on Thursday . The stock traded as low as $3.68 and last traded at $4.77, 1,832,482 shares were traded during mid-day trading. An increase of 1,128% from the average session volume of 149,266 shares. The stock had previously closed at $5.07.
Several brokerages recently commented on CTSO. B. Riley set a $12.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Friday, July 19th. Maxim Group set a $14.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine cut Cytosorbents from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Cytosorbents in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $13.67.
The stock has a market capitalization of $173.47 million, a P/E ratio of -8.52 and a beta of 1.50. The firm has a 50-day moving average of $6.65 and a 200 day moving average of $7.13. The company has a quick ratio of 3.00, a current ratio of 3.21 and a debt-to-equity ratio of 0.87.
Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Tuesday, August 6th. The medical research company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.53 million. Cytosorbents had a negative return on equity of 105.97% and a negative net margin of 72.43%. Analysts predict that Cytosorbents Corp will post -0.5 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of CTSO. Skylands Capital LLC lifted its position in Cytosorbents by 28.3% in the first quarter. Skylands Capital LLC now owns 636,050 shares of the medical research company’s stock worth $4,815,000 after purchasing an additional 140,200 shares during the period. Deutsche Bank AG lifted its position in Cytosorbents by 168.3% in the fourth quarter. Deutsche Bank AG now owns 160,546 shares of the medical research company’s stock worth $1,297,000 after purchasing an additional 100,717 shares during the period. Avenir Corp lifted its position in Cytosorbents by 66.6% in the second quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock worth $960,000 after purchasing an additional 58,060 shares during the period. Granite Investment Partners LLC lifted its position in Cytosorbents by 87.8% in the first quarter. Granite Investment Partners LLC now owns 110,530 shares of the medical research company’s stock worth $837,000 after purchasing an additional 51,679 shares during the period. Finally, Bank of America Corp DE lifted its position in Cytosorbents by 127.8% in the fourth quarter. Bank of America Corp DE now owns 83,489 shares of the medical research company’s stock worth $675,000 after purchasing an additional 46,840 shares during the period. 26.35% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Company Profile (NASDAQ:CTSO)
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.